Clinical Trial

Serum IGF-1 and IGF-1Ec in Malignancy Assessment

Study acronym: SIGMA
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 3, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
This cross-sectional study investigates the relationship between serum IGF-1 and IGF-1Ec (E-peptide/MGF) levels and tumor burden in patients with solid tumors. By analyzing serum samples using ELISA and correlating them with clinical data such as tumor stage, size, metastasis, and lymph node involvement, the study aims to explore whether these biomarkers-particularly IGF-1Ec and the IGF-1Ec/IGF-1 ratio-can reflect tumor progression and serve as potential prognostic indicators.
Trial Details
NCT Number NCT07151807
Lead Sponsor Çanakkale Onsekiz Mart University
Conditions Cancer, Solid Tumor Malignancies, IGF1R, Solid Cancers
Enrollment 100 participants
Start Date 2025-04-01
Primary Completion 2025-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-03